Emily Mullin, who had been reporting on biotech for Medium’s OneZero publication, is among those who have taken its buyout offer.
“I’m grateful to have had the opportunity to pursue meaningful stories about biotechnology and society over the past two years,” she wrote on Twitter.
Mullen was previously a freelance writer who has had bylines in The Washington Post, The Wall Street Journal, Scientific American, National Geographic, The Atlantic, Science, Quartz, Pacific Standard, and The Baltimore Sun, among others.
Her areas of interest include gene therapy, CRISPR, consumer genetics, reproductive technology, brain implants, regenerative medicine, biohacking, and AI in medicine.
She has also worked as associate editor for biomedicine at MIT Technology Review, where she earned a Newsbrief Award from the D.C. Science Writers Association.
She earned her bachelor’s degree in journalism at Ohio University and a master’s in science writing from Johns Hopkins University.
The Star Tribune is seeking an accomplished, motivated and versatile journalist and leader to shape…
The Deputy AME-Business is responsible for the development and planning of coverage on all Newsday…
CNBC.com managing editor Jeff McCracken announced Friday the following promotions: In San Francisco, Ari Levy has…
This Newsday reporter will cover Long Island’s commercial real estate market and the region’s evolving…
The New York Times is looking for a versatile editor to edit enterprise and feature…
International editor Matt Lamers is leaving Marijuana Business Daily. He has been there for seven years. Lamers…